Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions.

Elgindi D, Petronic-Rosic V

Clinics in dermatology3 Sept 2026

PMID42692277DOI10.1016/j.clindermatol.2026.08.012PepBankPUB-42692277

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studySafety outcome
In FAERS, skin and injection-site reactions comprised 33.5% of dulaglutide reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 33.5% of dulaglutide reports.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Measurements
Reporting proportion
33.5%
dulaglutide reports
Source sentences
Summary
Exenatide demonstrated the highest proportion of skin and injection-site reports (53.1%), followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%), and lixisenatide (6.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
Report a problemFND-4269227705
02HumanObservational studySafety outcome
In FAERS, skin and injection-site reactions comprised 17.1% of liraglutide reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 17.1% of liraglutide reports.
Peptide
Liraglutide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Measurements
Reporting proportion
17.1%
liraglutide reports
Source sentences
Summary
Exenatide demonstrated the highest proportion of skin and injection-site reports (53.1%), followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%), and lixisenatide (6.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
Report a problemFND-4269227706
03HumanObservational studySafety outcome
In FAERS, skin and injection-site reactions comprised 12.2% of semaglutide reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 12.2% of semaglutide reports.
Peptide
Semaglutide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Measurements
Reporting proportion
12.2%
semaglutide reports
Source sentences
Summary
Exenatide demonstrated the highest proportion of skin and injection-site reports (53.1%), followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%), and lixisenatide (6.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
Report a problemFND-4269227707
04HumanObservational studySafety outcome
In FAERS, skin and injection-site reactions comprised 32.6% of tirzepatide reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 32.6% of tirzepatide reports.
Peptide
Tirzepatide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Measurements
Reporting proportion
32.6%
tirzepatide reports
Source sentences
Summary
Exenatide demonstrated the highest proportion of skin and injection-site reports (53.1%), followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%), and lixisenatide (6.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
Report a problemFND-4269227708

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pooled GLP-1 FAERS reports, skin and injection-site reactions accounted for 31.0% of reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 31.0% of pooled GLP-1 reports.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Measurements
Reporting proportion
31%
pooled GLP-1 reports
Source sentences
Summary
Among 442,567 Food and Drug Administration Adverse Event Reporting System reports, 137,412 (31.0%) involved skin and injection-site reactions, representing the third most frequently reported adverse event category.
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4269227701
06HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled GLP-1 FAERS reports, skin and injection-site reactions accounted for 31.0% of reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 31.0% of pooled GLP-1 reports.
Peptide
Liraglutide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Measurements
Reporting proportion
31%
pooled GLP-1 reports
Source sentences
Summary
Among 442,567 Food and Drug Administration Adverse Event Reporting System reports, 137,412 (31.0%) involved skin and injection-site reactions, representing the third most frequently reported adverse event category.
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4269227702
07HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled GLP-1 FAERS reports, skin and injection-site reactions accounted for 31.0% of reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 31.0% of pooled GLP-1 reports.
Peptide
Semaglutide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Measurements
Reporting proportion
31%
pooled GLP-1 reports
Source sentences
Summary
Among 442,567 Food and Drug Administration Adverse Event Reporting System reports, 137,412 (31.0%) involved skin and injection-site reactions, representing the third most frequently reported adverse event category.
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4269227703
08HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In pooled GLP-1 FAERS reports, skin and injection-site reactions accounted for 31.0% of reports.
In plain wordsClinical adverse event reports showed skin and injection-site reactions in 31.0% of pooled GLP-1 reports.
Peptide
Tirzepatide
Outcome
Not applicableSkin and injection-site reporting proportion
Study
Homo sapiensn: not reported in source
FDA Adverse Event Reporting System clinical adverse event reports
Outcome group
Adverse events · Skin and wound
Measurements
Reporting proportion
31%
pooled GLP-1 reports
Source sentences
Summary
Among 442,567 Food and Drug Administration Adverse Event Reporting System reports, 137,412 (31.0%) involved skin and injection-site reactions, representing the third most frequently reported adverse event category.
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System.
Summary · context
Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4269227704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 6Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 5
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.